Riyad Tarazi1, Mustafa Ridha2, Mohammad Shammsah3, Khaldoon AlHumood2, Jean Tesreni1, Mohamed Badawy1,4, Amir Mohamed1,5, Adel Maher1,6. 1. Department of Cardiac Surgery, Al-Dabbous Cardiac Center, Kuwait City, Kuwait. 2. Department of Cardiology, Al-Dabbous Cardiac Center, Kuwait City, Kuwait. 3. Department of Cardiac Anesthesia, Al-Dabbous Cardiac Center, Kuwait City, Kuwait. 4. Department of Cardiothoracic Surgery, Ain Shams University, Cairo, Egypt. 5. Department of Cardiothoracic Surgery, Alexandria University, Alexandria, Egypt. 6. Department of Cardiothoracic Surgery, Aswan University, Aswan, Egypt.
Abstract
BACKGROUND: Heart Failure is an epidemic with a current prevalence of over 5.8 million patients in the USA and almost 23 million patients worldwide, with high associated mortality risks. The severe shortage of donor organs for cardiac transplants and increasing number of heart failure patients has led to the increasing popularity of left ventricular assist device (LVAD) therapy for treatment of end-stage heart failure patients. This paper describes our initial clinical experience with LVAD therapy of heart failure patients at our clinic. METHODS: Ten patients (eight males and two females) with a mean age of 48 years (range, 14-68 years) were implanted with LVADs as bridge to transplantation (BT) or destination therapy (DT) at our clinic between January 2015 and October 2017. RESULTS: Preliminary results were very promising with 0% 30-day mortality rates and no major surgical complications or LVAD thrombosis. CONCLUSIONS: Such results of LVAD implantation in Kuwait indicate the feasibility of establishing De Novo LVAD programs in low volume LVAD centers (≤10 implants/year) with promising results and offer a new era of hope for treating advanced heart failure patients.
BACKGROUND: Heart Failure is an epidemic with a current prevalence of over 5.8 million patients in the USA and almost 23 million patients worldwide, with high associated mortality risks. The severe shortage of donor organs for cardiac transplants and increasing number of heart failure patients has led to the increasing popularity of left ventricular assist device (LVAD) therapy for treatment of end-stage heart failure patients. This paper describes our initial clinical experience with LVAD therapy of heart failure patients at our clinic. METHODS: Ten patients (eight males and two females) with a mean age of 48 years (range, 14-68 years) were implanted with LVADs as bridge to transplantation (BT) or destination therapy (DT) at our clinic between January 2015 and October 2017. RESULTS: Preliminary results were very promising with 0% 30-day mortality rates and no major surgical complications or LVAD thrombosis. CONCLUSIONS: Such results of LVAD implantation in Kuwait indicate the feasibility of establishing De Novo LVAD programs in low volume LVAD centers (≤10 implants/year) with promising results and offer a new era of hope for treating advanced heart failure patients.
Authors: Soon J Park; Kenneth K Liao; Romualdo Segurola; K P Madhu; Leslie W Miller Journal: J Thorac Cardiovasc Surg Date: 2004-01 Impact factor: 5.209
Authors: Christian Jung; Georg Fuernau; Suzanne de Waha; Ingo Eitel; Steffen Desch; Gerhard Schuler; Hans R Figulla; Holger Thiele Journal: Clin Res Cardiol Date: 2015-02-27 Impact factor: 5.460
Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-02-23 Impact factor: 29.690
Authors: Jan D Schmitto; Jasmin S Hanke; Sebastian V Rojas; Murat Avsar; Axel Haverich Journal: J Heart Lung Transplant Date: 2015-03-07 Impact factor: 10.247
Authors: David Feldman; Salpy V Pamboukian; Jeffrey J Teuteberg; Emma Birks; Katherine Lietz; Stephanie A Moore; Jeffrey A Morgan; Francisco Arabia; Mary E Bauman; Hoger W Buchholz; Mario Deng; Marc L Dickstein; Aly El-Banayosy; Tonya Elliot; Daniel J Goldstein; Kathleen L Grady; Kylie Jones; Katarzyna Hryniewicz; Ranjit John; Annemarie Kaan; Shimon Kusne; Matthias Loebe; M Patricia Massicotte; Nader Moazami; Paul Mohacsi; Martha Mooney; Thomas Nelson; Francis Pagani; William Perry; Evgenij V Potapov; J Eduardo Rame; Stuart D Russell; Erik N Sorensen; Benjamin Sun; Martin Strueber; Abeel A Mangi; Michael G Petty; Joseph Rogers Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: Jan D Schmitto; Daniel Zimpfer; Arnt E Fiane; Robert Larbalestier; Steven Tsui; Paul Jansz; Andre Simon; Stephan Schueler; Martin Strueber Journal: Eur J Cardiothorac Surg Date: 2016-07-13 Impact factor: 4.191
Authors: Hideki Tsubota; Roberto V P Ribeiro; Filio Billia; Robert J Cusimano; Terrence M Yau; Mitesh V Badiwala; William E Stansfield; Vivek Rao Journal: Can J Surg Date: 2017-08 Impact factor: 2.089
Authors: Thibault Schaeffer; Otmar Pfister; Constantin Mork; Paul Mohacsi; Florian Rueter; Simon Scheifele; Anne Morgen; Urs Zenklusen; Thomas Doebele; Markus Maurer; Joachim Erb; Jens Fassl; Nadine Cueni; Martin Siegemund; Hans Pargger; Brigitta Gahl; Stefan Osswald; Friedrich Eckstein; Martin Grapow Journal: J Cardiothorac Surg Date: 2021-03-31 Impact factor: 1.637